17 results on '"Sottotetti E"'
Search Results
2. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab
3. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab
4. SO-20 Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study
5. SO-24 Circulating tumor DNA variant allelic fraction as a surrogate for disease burden estimation in patients with RAS wild-type metastatic colorectal cancer: A secondary endpoint of the VALENTINO study
6. Analysis of circulating biomarkers in a randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study
7. Pro-GRP in small cell lung cancer
8. 139P - Analysis of circulating biomarkers in a randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study
9. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer according to body mass index
10. Risk of thromboembolic events (TEE) in metastatic colorectal cancer (mCRC) patients with single nucleotide polymorphisms (SNPs) in Factor V Leiden (FVL), Prothrombin, Plasminogen Activator Inhibitor-1 (PAI-1) and Methylenetetrahydrofolate Reductase (MTHFR)
11. 56P - Pro-GRP in small cell lung cancer
12. Prospective Observational Study for Dpyd and Ugt1A1 Deficiency-Associated Toxicity in Patients with Metastatic Colorectal Cancer (Mcrc) Receiving Triplet Chemotherapy with Capecitabine, Irinotecan and Oxaliplatin (Coi)
13. Circulating Tumor Cells (CTCS) as Prognostic Biomarker in Patients with Advanced Chemorefractory, Ras Wild-Type Colorectal Cancer (CRC) Treated with Cetuximab or Panitumumab
14. E16 - Risk of thromboembolic events (TEE) in metastatic colorectal cancer (mCRC) patients with single nucleotide polymorphisms (SNPs) in Factor V Leiden (FVL), Prothrombin, Plasminogen Activator Inhibitor-1 (PAI-1) and Methylenetetrahydrofolate Reductase (MTHFR)
15. A31 - Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer according to body mass index
16. 532P - Prospective Observational Study for Dpyd and Ugt1A1 Deficiency-Associated Toxicity in Patients with Metastatic Colorectal Cancer (Mcrc) Receiving Triplet Chemotherapy with Capecitabine, Irinotecan and Oxaliplatin (Coi)
17. PD-0011 - Circulating Tumor Cells (CTCS) as Prognostic Biomarker in Patients with Advanced Chemorefractory, Ras Wild-Type Colorectal Cancer (CRC) Treated with Cetuximab or Panitumumab
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.